Genes Tech Group Holdings Company Limited (8257) AI Stock Analysis

• Market Cap: HK$131.00M
• Dividend Yield: N/A
• Average Volume (3M): 589.00K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 1.43
• Revenue Growth: -13.07%
• EPS Growth: -34.88%
• Country: HK
• Employees: 260
• Sector: Technology
• Sector Strength: 88
• Industry: Semiconductors
• EPS (TTM): 0.01
• Shares Outstanding: 1,000,000,000
• 10 Day Avg. Volume: 833,000
• 30 Day Avg. Volume: 589,000
• PEG Ratio: -0.22
• Price to Book (P/B): 0.48
• Price to Sales (P/S): 0.42
• P/FCF Ratio: 4.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: HK$0.00 ▼(-100.00% Downside)

The stock's overall score is driven by strong technical momentum and improving financial performance. While valuation is moderate, the lack of dividend yield and declining revenue are concerns. The absence of recent earnings call data limits insights into future guidance.

Genes Tech Group Holdings Company Limited Business Overview & Revenue Model

Company Description

Genes Tech Group Holdings Company Limited (8257) is a biotechnology firm based in Hong Kong, specializing in the development and commercialization of innovative genetic testing and analysis solutions. The company's core offerings include genetic testing services for various health conditions, as well as advanced genomic research technologies aimed at enhancing personalized medicine and improving patient outcomes. Genes Tech operates within the healthcare sector, focusing on the integration of cutting-edge technology with genomic data to provide actionable insights for healthcare providers and patients alike.

How the Company Makes Money

Genes Tech Group generates revenue primarily through its genetic testing services, which include a range of diagnostic tests that cater to both individual consumers and healthcare professionals. The company charges fees for these tests, which can vary based on the complexity and type of analysis performed. Additionally, Genes Tech may earn income through partnerships with healthcare institutions, laboratories, and pharmaceutical companies, providing research and development services that leverage its expertise in genomics. The company's revenue model may also include subscription-based services for ongoing genomic analysis or data access, as well as potential royalties from licensing its technologies to third parties. Strategic alliances and collaborations with other stakeholders in the healthcare and biotech fields play a significant role in expanding its market reach and enhancing its earnings potential.

Genes Tech Group Holdings Company Limited Financial Statement Overview

Summary

Genes Tech Group Holdings Company Limited's financial performance shows signs of recovery with improved operational efficiencies and stable balance sheet. Despite declining revenue, better margins and improved cash flows highlight successful capital management.

Income Statement

The income statement shows declining revenue with a decrease from 2023 to 2024. The net profit margin in 2024 was 2.6%, which indicates low profitability. However, gross profit margin improved from 24.4% in 2023 to 28.2% in 2024, suggesting better cost control. EBIT and EBITDA margins were also positive in 2024, indicating operational improvements.

Balance Sheet

The balance sheet reflects a relatively stable financial position with a debt-to-equity ratio of 0.76 in 2024, showing moderate leverage. The equity ratio of 33.6% suggests a decent level of equity backing the assets. The return on equity improved to 3.0% in 2024, indicating some recovery in profitability.

Cash Flow

The cash flow statement shows a significant improvement in operating cash flow, turning positive in 2024. The free cash flow to net income ratio suggests strong cash generation relative to net income. Free cash flow growth was notable, indicating better capital management and liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	982.26M	931.96M	1.33B	1.60B	1.50B	1.50B
Gross Profit	308.72M	263.33M	325.96M	107.48M	342.17M	399.92M
EBITDA	154.90M	152.99M	188.02M	-26.13M	173.37M	248.27M
Net Income	34.28M	24.28M	90.64M	-80.44M	79.40M	144.20M
Balance Sheet
Total Assets	2.56B	2.44B	2.10B	2.48B	2.56B	2.46B
Cash, Cash Equivalents and Short-Term Investments	205.58M	194.29M	152.33M	242.33M	176.88M	96.21M
Total Debt	594.15M	620.03M	635.57M	682.63M	657.80M	756.51M
Total Liabilities	1.67B	1.62B	1.30B	1.77B	1.76B	1.69B
Stockholders Equity	888.72M	820.48M	805.61M	712.51M	801.21M	770.05M
Cash Flow
Free Cash Flow	154.94M	91.22M	-23.15M	64.43M	248.85M	26.07M
Operating Cash Flow	159.20M	94.55M	-11.18M	82.49M	254.14M	63.56M
Investing Cash Flow	-4.08M	-2.19M	-10.91M	-17.63M	-5.19M	-37.35M
Financing Cash Flow	-101.80M	-55.04M	-66.58M	-11.42M	-170.79M	-63.85M

Genes Tech Group Holdings Company Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8257, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 76.59 is Negative, neither overbought nor oversold. The STOCH value of 67.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8257.

Genes Tech Group Holdings Company Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8257	70 Outperform	HK$131.00M	15.60	3.83%	―	-13.07%	-34.88%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
1967	55 Neutral	HK$130.50M	-15.65	-2.32%	―	-6.45%	-596.43%
8490	46 Neutral	HK$99.48M	―	-41.46%	―	-26.02%	-4977.27%
0243	46 Neutral	HK$133.40M	-104.05	-0.33%	―	14.75%	98.26%
1912	46 Neutral	HK$98.83M	―	―	―	-6.19%	18.71%
1679	40 Underperform	HK$125.17M	-0.95	―	―	37.63%	56.51%